Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | TYMS | P04818 | 2/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.33 |
| ▸ | KLK1 | P06870 | 2/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25826362 | 0.81 | CYP17A1 (0.49) | UHRF1NOS3NOS1NOS2KCNQ2 | |
| SCHEMBL12362963 | 0.76 | CYP3A4 (0.52) | UHRF1NOS3NOS1NOS2KCNQ2 | |
| SCHEMBL19335823 | 0.73 | UHRF1 (0.39) | UHRF1KCNQ2RAB9A | |
| SCHEMBL20756914 | 0.73 | UHRF1 (0.46) | UHRF1KCNQ2RAB9A | |
| SCHEMBL25826448 | 0.73 | UHRF1 (0.36) | PIK3CBUHRF1NOS3NOS1NOS2 | |
| SCHEMBL27323925 | 0.73 | LOXL2 (0.44) | UHRF1NOS3NOS1NOS2KCNQ2 | |
| SCHEMBL22604676 | 0.72 | UHRF1 (0.50) | UHRF1KCNQ2FLT1KDR | |
| SCHEMBL1563564 | 0.72 | CALM1 (0.48) | UHRF1NOS2KCNQ2FLT1KDR | |
| SCHEMBL5037060 | 0.71 | EPHX2 (0.47) | GAARAB9A | |
| SCHEMBL19335859 | 0.70 | CYP11B1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | PIK3CB 15/4885UHRF1 3902/4885NOS3 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.